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procured, provides alternatives to adjust the budget available and release financial 
resources for cost effective and sustainable interventions .
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Objectives: To be effective, osteoporosis (OP) therapy must be taken consistently 
and as prescribed. Persistence is critical for successful outcomes, including fracture 
risk reduction. Few studies compare the persistence of oral bisphosphonate (BPs), IV 
BPs and denosumab beyond 1 year. This retrospective database analysis evaluated 
2-year persistence to oral BPs, IV BPs and denosumab following treatment initiation 
and the risk of treatment discontinuation. MethOds: From the German IMS®LRx 
database, we included women aged ≥ 45 years who initiated an OP treatment after 
1-July-2010 (index date = treatment initiation) with ≥ 2 years of follow-up until 
31-Dec-2014. Persistence (prescription refill gap ≤ 60 days and no drug switch) was 
measured for 2 years from index date, and a Cox proportional hazard regression 
model was used to estimate the risk of treatment discontinuation (i.e. non-persis-
tence). Results: Data from 159,993 women were included in the analysis. Two years 
after treatment initiation, 39.8 % of those receiving denosumab (n= 21,154), 24.8 % 
receiving IV ibandronate (n= 20,472), 21.2 % receiving IV zoledronic acid (n= 3,966), 
and 16.7 %„Ÿ17.5 % of those receiving oral BPs were persistent. Compared with those 
receiving denosumab, women receiving IV ibandronate or IV zoledronic acid were 
at higher risk of treatment discontinuation (HR [95% CI]: 1.65 [1.61-1.69] and 1.28 
[1.23-1.33] respectively; p< 0.001 for both). Moreover, women treated with oral BPs vs 
denosumab showed a two-fold risk of treatment discontinuation (HR [95% CI]: 2.02 
[1.98-2.06] for alendronate, 2.02 [1.95-2.09] for ibandronate and 1.96 [1.91-2.01] for 
risedronate; p< 0.001 for all). cOnclusiOns: In our database study of women ini-
tiating BPs (oral or IV) or denosumab in routine clinical practice, 2-year persistence 
was highest for denosumab (1.5-2 times higher). Moreover, compared to denosumab, 
women treated with oral or IV BPs were at higher risk of treatment discontinuation. 
Such improved persistence may improve clinical outcomes, including increased 
fracture risk reduction.
PMS133
Self-rePorTed rheuMaTic diSeaSeS and early reTireMenT in PorTuGal
Laires PA1, Gouveia M2, Canhão H1, Rodrigues A3, Gouveia N3, Eusébio M3, Branco JC3
1Faculdade de Medicina da Universidade de Lisboa, Lisbon Academic Medical Center, Lisbon, 
Portugal, Lisbon, Portugal, 2Católica Lisbon School of Business and Economics, Lisbon, Portugal, 
3Sociedade Portuguesa de Reumatologia, Lisbon, Portugal
Objectives: We aim to examine the association between self-reported RD and early 
retirement by using large real-world observational data in Portugal. MethOds: We 
used individual level data from the national, population-based EpiReumaPt study 
(September 2011 to December 2013). 10,661 inhabitants were randomly surveyed in 
order to capture and characterize all cases of RD within a representative sample of 
the Portuguese population, which were stratified by administrative territorial units 
(NUTSII). In this analysis we used all participants aged between 50 and 65 years old, 
near the official retirement age (N= 2,792; females: 1,727). The association of self-
reported RD and early retirement was tested using logistic regression. All estimates 
were computed as weighted proportions, in order to take into account the sampling 
design. Results: 29.9% of the Portuguese population with ages between 50 and 64 
years old were officially retired. Among these, 43.2% were retired due to ill-health, 
which in turn about a third (30.4%) was specifically due to RD. Thus, 13.1% of all 
retirees self-reported RD as the main reason for early retirement. More than a third 
(34.2%; females: 46.3%) of all study population self-reported RD, being also more 
likely to self-report other main chronic disease (OR: 3.4; CI: 2.53-4.65; p< 0.001). 35.2% 
of RD respondents were retired versus 27.2% of those non-RD (p= 0.025). Prevalence 
of self-reported RD seems to be associated with early retirement (unadjusted OR: 
1.45; CI: 1.05-2.01; p= 0.025). Some other characteristics are also associated with 
early retirement, in particular older age, male gender and presence of other chronic 
diseases. RD association tends to be independently associated with early retire-
ment (adjusted OR: 1.41; CI: 1.03-1.95; p= 0.031). cOnclusiOns: These results are 
similar with previous data from the National Health Survey conducted in Portugal 
nearly a decade ago and confirms the impact that self-reported RD still have on 
early retirement.
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Objectives: To assess demographic and disease characteristics of rheumatoid 
arthritis (RA) patients starting treatment with biologic disease-modifying anti-rheu-
matic drugs (DMARDs) in observational studies. MethOds: Systematic review of 
published observational studies in adult patients with RA treated with one of three 
biologic DMARDs (etanercept, rituximab, tocilizumab). We identified eligible studies 
through electronic searches of the MEDLINE and EMBASE databases. Two reviewers 
screened the articles independently. We extracted study characteristics such as 
location and calendar period, demographics of study populations, dose, frequency 
and concomitant therapies, and baseline characteristics such as disease duration, 
the most common bone disease and its incidence is rapidly increasing with the 
aging population. Even if curable, it is often left untreated causing a moderate use 
of economic resources that could be avoided.
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Objectives: Hospital Parc Taulí and Johnson & Johnson, partnered in a program 
to design and implant a fast track program for knee joint replacement. The objec-
tive was to decrease morbidity, functional convalesce, length of stay and increase 
patient and professionals satisfaction efficiently. MethOds: The implementation 
included 3 phases and two multidisciplinary Workgroups. Clinical aspects based on 
evidence, combined with organizational optimization, resources distribution and 
process redesign. Phase I: evaluation, nourished by Kaizen methodologies, Lean 
and 6 Sigma processes, Blum and Taylor laborer environment and Alex Faicknet 
Osborn group dynamics were taken under consideration. Phase II: Implantation, 
using Taylor dynamics to define the strategies to produce improvement on target 
indicators. Phase III: Monitoring, both from length of stay, security aspects such as 
morbidity, mortality, readmission rates, patient and professional satisfaction, and 
economic impact. Results: The length of stay is influenced by factors such as 
patient profile and organizational aspects. Empowered patients are more active. 
A new patient pathway was developed, initiated when admitted to discharge and 
post-operative follow up. Improvement on healthcare results, increasing patient and 
professional’s satisfaction, and reducing 50% length of stay, resulting on significant 
economical savings. cOnclusiOns: Analyzing the patient pathway through an 
analysis methodology, reingeniery and diagnosis healthcare process (in outcomes 
and in direct cost), the patient involvement in the whole process can result not only 
in important efficiency improvement, but also improve the working environment 
and enhanced team work culture for a continuous process improvement.
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Objectives: The emergence of biosimilars for blockbuster therapies such as 
Remicade, Humira, Enbrel and Rituxan/MabThera is changing the paradigm by which 
traditional market access decisions are made for biologics. Furthermore, the regula-
tory pathway in Europe and the U.S. has raised uncertainties among clinicians regard-
ing both the efficacy and safety of biosimilar molecules. The objectives of our research 
were to (1) understand the evolving mechanisms for biosimilar market access, (2) 
identify the key stakeholders involved in access decisions or influence and (3) deter-
mine the value drivers of biosimilars across diverse stakeholder groups. MethOds: 
A large sample of stakeholders (n= 271) were engaged, including clinical specialists, 
payers and patients, across Europe and in the U.S. We performed in-depth qualita-
tive interviews to gain an understanding of the current landscape for biologics and 
expectations for biosimilars, focusing on RA, Ulcerative Colitis, Crohn’s Disease and 
Psoriasis. Results: Our research indicates the fundamental understanding of bio-
similars is inconsistent both within stakeholder groups and across different groups. 
Furthermore, for clinicians, a lack of accurate understanding of biosimilars can be a 
substantial driver of negative perception and a key barrier to anticipated adoption. 
Overall, each stakeholder group that will influence biosimilar market access has dif-
ferent value needs and expectations from biosimilars. cOnclusiOns: Our findings 
highlight the need for a more consistent definition of biosimilar and clinical data 
requirements and a tailored approach to value communication for key influencers 
and stakeholders in the biosimilar value chain.
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Objectives: In 2014, the budget for high cost drugs in Dominican Republic (DR) was 
USD 107 million, accounting for 51% of the MoH budget for medicines. Resources 
allocated for the 2015 budget were USD 49 million, leaving a shortfall of USD 62 
million. The MoH requested technical assistance from the USAID funded SIAPS 
project to conduct an evidence based analysis of the 98 products included in the 
list. MethOds: Stage 1. Gathering of Evidence and Analysis; SIAPS consultant ana-
lyzed the therapeutic benefits and cost, and proposed 4 priority levels: Priority 1: 
Medicines included in the WHO Essential Medicine List; Priority 2: Included in the 
list of a Central America and DR procurement mechanism (COMISCA); Priority 3: Not 
included in the preceding groups but with scientific evidence of therapeutic benefits 
and approved by EMA and FDA; Priority 0: Medicines for which evidence on benefits 
was insufficient or for which better/cheaper alternatives were available. Stage 2. 
Review and approval by national scientific committee. During a two-day workshop, 
clinical specialists reviewed the proposed priority groups, consulted literature and 
proposed modifications supported by scientific evidence. Results: In the plenary 
session, the scientific committee, agreed by consensus on the final version of the 
high cost drugs list to be procured in 2015. Of the 98 medicines, 22 were on the 
WHO list and 17 were on the COMISCA; 14 of the remaining 59 medicines were also 
included because there was scientific evidence of its benefits. Total of 45 medicines 
were removed by consensus, with a budget decrease of 53 % and savings of USD 
21 million. cOnclusiOns: A review -based on evidence- followed by a consensus 
reached with clinical specialists allowed to select the number of products to be 
